Glycemic status and risk of prostate cancer.

Abstract

BACKGROUND To examine the risk of prostate cancer and glucose tolerance in a large, racially diverse cohort. METHODS We conducted a cohort study of 47,209 male members of Kaiser Permanente Northern California who had completed at least one Multiphasic Health Checkup (MHC) between 1964 and 1973. The MHC provided information on diabetes, serum glucose 1 h after a 75-g oral glucose challenge test, demographics, and other health conditions. Cox proportional hazards were used to estimate relative risks (RR) while adjusting for confounders. RESULTS During a median follow-up of 18.4 years, a total of 2,833 men developed prostate cancer. At baseline, 4.6% (n = 2,159) of the cohort had diabetes and 33% had serum glucose of >or=200 mg/dL. After adjusting for age, race, birth year, and body mass index, RR (95% confidence interval) of prostate cancer associated with 1-h serum glucose >or=200 mg/dL and diabetes were 0.90 (0.81-1.01) and 0.71 (0.62-0.79), respectively, when compared with those with serum glucose <140 mg/dL. During the first 10 years of follow-up, risk was increased among those with serum glucose >or=200 mg/dL or diabetes [RR (95% confidence interval), 1.42 (0.95-2.13) and 1.56 (0.91-2.67), respectively]. In contrast, inverse associations between serum glucose >or=200 mg/dL and diabetes and prostate cancer risk were observed [0.87 (0.77-0.97) and 0.68 (0.52-0.88), respectively] when follow-up began 10 years after MHC. CONCLUSION Our findings are consistent with the hypothesis that prostate cancer risk differs by time since diabetes diagnosis or occurrence of metabolic aberrations associated with impaired glucose tolerance.

DOI: 10.1158/1055-9965.EPI-07-2610

3 Figures and Tables

Statistics

0204020102011201220132014201520162017
Citations per Year

62 Citations

Semantic Scholar estimates that this publication has 62 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Darbinian2008GlycemicSA, title={Glycemic status and risk of prostate cancer.}, author={Jeanne A. Darbinian and Assiamira Ferrara and Stephen K Van Den Eeden and Charles Price Quesenberry and Bruce Fireman and Laurel A. Habel}, journal={Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology}, year={2008}, volume={17 3}, pages={628-35} }